{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:58:25Z","timestamp":1778803105950,"version":"3.51.4"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Neuropsychiatric symptoms and syndromes are among the most common non-motor symptoms of Parkinson's Disease but they are frequently unrecognized and untreated. Dopamine Dysregulation Syndrome is an uncommon complication of the treatment of Parkinson's disease, characterized by an addictive use of dopamine far more than the dosage required for treatment of objective motor impairment, leading to severe dyskinesia, euphoria, aggressivity, or psychosis. We present a paradigmatic case of Dopamine Dysregulation Syndrome, Mania, and Compulsive Buying in a 55-year-old male with Parkinson's Disease. We also reviewed the risk factors and the therapeutic management of Dopamine Dysregulation Syndrome in Parkinson's Disease.<\/jats:p>","DOI":"10.3389\/fneur.2023.1290653","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T10:35:45Z","timestamp":1700822145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Dopamine Dysregulation Syndrome, mania, and compulsive buying in a patient with Parkinson's disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Carlos","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rebelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Chendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.neurol.2012.06.014","article-title":"Basal ganglia and limbic system: a new frontier - Addictive behaviors and Parkinson's disease","volume":"168","author":"Witjas","year":"2012","journal-title":"Reveu Neurologique."},{"key":"B3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: from clinical neuropsychological characterization to management long-term outcome","volume":"85","author":"Cilia","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/mdc3.12671","article-title":"The outcome of dopamine dysregulation syndrome in Parkinson's disease: a retrospective postmortem study","volume":"5","author":"Barbosa","year":"2018","journal-title":"Mov Disord Clin Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.parkreldis.2014.01.001","article-title":"Hypomania and mania related to dopamine replacement therapy in Parkinson's disease","volume":"20","author":"Maier","year":"2014","journal-title":"Parkinson Relat Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/mds.20288","article-title":"Prevalence and clinical features of hedonistic dysregulation syndrome in Parkinson's disease","volume":"20","author":"Pezzella","year":"2005","journal-title":"Mov Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviors in Parkinson's disease","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","article-title":"Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms","volume":"8","author":"Rodriguez-Oroz","year":"2009","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0447.2007.01058.x","article-title":"Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder","volume":"116","author":"Berk","year":"2007","journal-title":"Acta Psychiatr Scand."},{"key":"B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/01.wco.0000137528.23126.41","article-title":"Dopamine dysregulation syndrome in Parkinson's disease","volume":"17","author":"Evans","year":"2004","journal-title":"Curr Opin Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1212\/01.wnl.0000183147.59483.ab","article-title":"Levodopa addiction in idiopathic Parkinson's disease","volume":"65","author":"Borek","year":"2005","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","article-title":"Impulse control and related disorders in Parkinson's disease","volume":"133","author":"Weintraub","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2017-315985","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases","volume":"88","author":"Warren","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O'Sullivan","year":"2009","journal-title":"CNS Drugs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00415-012-6669-1","article-title":"Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease","volume":"260","author":"Sriram","year":"2013","journal-title":"J Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-016-0341-8","article-title":"Valproate-associated Parkinsonism: a critical review of the literature","volume":"30","author":"Brugger","year":"2016","journal-title":"CNS Drugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans","year":"2006","journal-title":"Ann Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1290653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T10:35:47Z","timestamp":1700822147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1290653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":17,"alternative-id":["10.3389\/fneur.2023.1290653"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1290653","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"article-number":"1290653"}}